-
Wearing Off Rates Higher in Ocrelizumab Than Ofatumumab, Study Suggests
02 Jun 2025 13:52 GMT
… symptom worsening while on medication than those prescribed ofatumumab (Kesimpta; Novartis). … medications to manage MS symptoms (68% vs 83%).
In the trial … with ocrelizumab, regardless of treatment duration. For ofatumumab, occurrence decreased with longer …
-
Pregnancy Outcomes in Ofatumumab-Treated Women Appear Consistent With General Population Rates
30 May 2025 20:15 GMT
… were treated with ofatumumab (Kesimpta; Novartis), an FDA-approved disease-modifying therapy … , drawing on cases from clinical trials and post marketing surveillance via … . ABSTRACT LBA14.
2. FDA approves Novartis Kesimpta® (ofatumumab), the first and only …
-
Statin use has ‘strong link’ to survival benefits for patients with certain blood cancers
12 May 2025 12:03 GMT
… addition of statin medications to contemporary therapies … recommend statins for cancer prevention or treatment based … trials — RESONATE, RESONATE-2, iLLUMINATE and HELIOS — in their study.
Each trial … drugs as monotherapy or in combination, including ofatumumab …
-
Statins May Improve Survival in Patients With Chronic Lymphocytic Leukemia Receiving Ibrutinib
06 May 2025 20:00 GMT
… ibrutinib (Imbruvica; Janssen Biotech, AbbVie). The study findings … treatment. Statins have been shown to reduce mortality across cancer … data from 4 randomized trials: RESONATE (NCT01578707), RESONATE2 … (PCI-32765) versus ofatumumab in patients with relapsed …
-
Concurrent Statin Use With Treatment Improves Survival in CLL/SLL
26 Apr 2025 02:12 GMT
Concurrent statin use with contemporary treatment regimens … varying across trials. RESONATE compared ibrutinib to ofatumumab (Kesimpta), … ;chlorambucil. The HELIOS trial combined ibrutinib with bendamustine … OS, PFS, and cancer-specific survival. A …
-
The emergence of BTK inhibitors in multiple sclerosis treatment: Companies close in on approval
23 Apr 2025 16:25 GMT
… therapies, like FDA-approved Ocrelizumab (Ocrevus) and Ofatumumab (Kesimpta), … trials in relapsing multiple sclerosis, and the FENtrepid trial … approved disease-modifying drug for the treatment of relapsing … to ditch Chinese biotech InnoCare Pharma’s BTK …
-
Optum Rx Reduces Over 10% of Overall Pharmacy Prior Authorizations, Impacting Dozens of Drugs
22 Apr 2025 19:32 GMT
… with pharmacists and other treatment providers. The policy … medicines features inclisiran (Leqvio; Novartis), evolocumab (Repatha; Amgen), ofatumumab … consumer access to prescription drugs. News Release. … authorization/what-doctors-wish-patients-knew-about …
-
FDA warns about possible increased risk of death and serious side effects with cancer drug Copiktra (duvelisib)
19 Feb 2025 23:30 GMT
… information was limited, and FDA required the drug manufacturer, Secura Bio, to … , Grade ≥3 adverse events, and treatment modifications due to adverse events … in the DUO Trial, ITT population
Copiktra (N=160)
Ofatumumab (N=159 …
-
General Oncology Appoints Seasoned Biotech Executive Abid Ansari as Chief Financial Officer
08 Apr 2025 13:00 GMT
… advances its proprietary treatment in metastatic pancreatic cancer. This is … of experience in the biotechnology and life sciences industries, … , Abid held positions at GlaxoSmithKline (GSK) in deal finance and … , the asset sale of ofatumumab to Novartis, and a …
-
Kesimpta interactions: Alcohol, medications, and other factors
07 Apr 2025 17:27 GMT
Kesimpta (ofatumumab) is a brand-name … Kesimpta.
Talk with your doctor about your medical history, including whether … treatment, talk with your doctor.
Here’s a closer look at certain drug … data from clinical trials to determine whether the drug passes into …
About
© 1995-2025